Dendritic cells are poised to revolutionize oncology. This type of immune therapy shows effectiveness even in late-stage ...

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...

Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight ...

Researchers develop a plug-and-play test that enables real-time monitoring of engineered T-cells, improving the precision and ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

The new machinery, called a "chimeric antigen receptor" or "Car," transforms a diverse T-cell population into Car-T, where the engineered cells all respond to the same cancer-associated marker. Both ...

A vaccine consists of immunogenic tumor-associated antigens, shaped as peptides ... a potentially important therapeutic target for immunotherapy. [42] Tumor cell vaccines expose the host immune ...

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...